Lexicon Pharmaceuticals has been granted a patent for a method of treating or managing SARS-CoV-2-like coronavirus infections. The method involves administering a compound called (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine, which is an adaptor associated kinase 1 inhibitor. GlobalData’s report on Lexicon Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lexicon Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. Lexicon Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating sars-cov-2-like coronavirus infection with a specific compound
A recently granted patent (Publication Number: US11666575B2) describes a method for treating or managing coronavirus infections. The method involves administering a compound called (S)-1-((2',6-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine to a subject in need of treatment.
The patent claims cover three specific types of coronavirus infections: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-like coronavirus, CoV-229E-like coronavirus, and CoV-OC43-like coronavirus. In each case, the method involves administering the compound to a subject in need of treatment.
The compound is administered in a therapeutically effective amount, meaning a dosage that is sufficient to produce the desired therapeutic effect. The compound can be administered orally, and it is typically formulated as a pharmaceutical composition that includes the compound and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition can be in the form of a dosage form, such as a tablet or capsule.
The patent also specifies certain characteristics of the coronavirus infections that can be treated using this method. For example, in the case of SARS-CoV-2-like coronavirus and CoV-229E-like coronavirus, the viruses should have at least 80, 90, 95, or 98 percent sequence identity with a specific sequence identified as SEQ ID NO 1 or SEQ ID NO 5, respectively. Similarly, for CoV-OC43-like coronavirus, the virus should have at least 80, 90, 95, or 98 percent sequence identity with a specific sequence identified as SEQ ID NO 9.
The method is intended for subjects who display symptoms commonly associated with coronavirus infections, such as fever, cough, shortness of breath, difficulty breathing, chest pain, tiredness, runny nose, or sore throat.
In summary, the granted patent describes a method for treating or managing coronavirus infections using a specific compound. The method involves administering the compound to a subject in need of treatment, and it is applicable to different types of coronavirus infections. The compound can be administered orally in the form of a pharmaceutical composition. The patent also specifies the characteristics of the viruses that can be treated using this method and the symptoms that may indicate the need for treatment.
To know more about GlobalData’s detailed insights on Lexicon Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
